PDCD1 and head and neck squamous cell carcinoma: On the other hand, the status of a phase I trial (NCT04139057), evaluating the maximum tolerated dose (MTD) of EBV-specific T cell receptor (TCR)-T cells with anti-PD1 auto-secreted elements, in patients with EBV-positive HNSCC is currently unknown.